一项新的试验发现, aza-ven 能够在适合的AML患者中胜过化疗, 增加了生存率和减少死亡率. A new trial finds aza-ven beats chemo for fit AML patients, doubling survival and reducing deaths.

一项新的临床试验表明,与传统化疗相比,azacitidine和venetoclax(aza-ven)的结合大大改善了新诊断的急性流血性白血病(AML)患者的适应性结果。 A new clinical trial shows that the combination of azacitidine and venetoclax (aza-ven) significantly improves outcomes for fit, newly diagnosed acute myeloid leukemia (AML) patients compared to traditional chemotherapy. 在一项对172名成年人的研究中,aza- even使无事件生存率翻了一番,达到14. 6个月,而不是6. 2个月,使早期死亡率降至零,并导致更高的应答率和更多符合干细胞移植条件的患者. In a study of 172 adults, aza-ven doubled event-free survival to 14.6 months versus 6.2 months, reduced early deaths to zero, and led to higher response rates and more patients eligible for stem cell transplants. 该制度还改善了生活质量,减少了住院治疗,并产生了类似的严重副作用。 The regimen also improved quality of life and reduced hospitalizations, with similar severe side effect rates. 这些结果支持将za-ven作为适合AML病人的更安全、更有效的前线选择,有可能取代密集化疗。 These results support aza-ven as a safer, more effective frontline option for fit AML patients, potentially replacing intensive chemotherapy.